Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVEILLE-HPV: HPV16 Ct-DNA for Oropharyngeal Cancer Surveillance
NCT05582122Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Unicancer. Primary endpoint: Negative Predictive Value of HPV16 ct-DNA at 24 months. Started Apr 2024; status: recruiting.
Beyond the preview
Go deeper on NCT05582122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582122.